ATE288502T1 - Gezieltes antikörper-verfahren - Google Patents

Gezieltes antikörper-verfahren

Info

Publication number
ATE288502T1
ATE288502T1 AT02788114T AT02788114T ATE288502T1 AT E288502 T1 ATE288502 T1 AT E288502T1 AT 02788114 T AT02788114 T AT 02788114T AT 02788114 T AT02788114 T AT 02788114T AT E288502 T1 ATE288502 T1 AT E288502T1
Authority
AT
Austria
Prior art keywords
methods
targeted antibody
vaccine
antibody process
vaccinating
Prior art date
Application number
AT02788114T
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Gordon Patrick Rigg
Peter Williamson
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE288502(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Application granted granted Critical
Publication of ATE288502T1 publication Critical patent/ATE288502T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT02788114T 2001-12-19 2002-12-16 Gezieltes antikörper-verfahren ATE288502T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130267.8A GB0130267D0 (en) 2001-12-19 2001-12-19 Focussed antibody technology
PCT/GB2002/005690 WO2003052416A2 (en) 2001-12-19 2002-12-16 Focussed antibody technology

Publications (1)

Publication Number Publication Date
ATE288502T1 true ATE288502T1 (de) 2005-02-15

Family

ID=9927861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02788114T ATE288502T1 (de) 2001-12-19 2002-12-16 Gezieltes antikörper-verfahren

Country Status (10)

Country Link
US (1) US20060233812A1 (de)
EP (1) EP1415002B1 (de)
AT (1) ATE288502T1 (de)
AU (1) AU2002352394A1 (de)
CA (1) CA2471570A1 (de)
DE (1) DE60202877T2 (de)
ES (1) ES2236605T3 (de)
GB (1) GB0130267D0 (de)
PT (1) PT1415002E (de)
WO (1) WO2003052416A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP2088432A1 (de) * 2008-02-11 2009-08-12 MorphoSys AG Verfahren zur Identifikation eines Antikörpers oder eines Targets
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
GB2477439B (en) 2008-11-07 2012-02-15 Sequenta Inc Methods for correlating clonotypes with a disease in a patient
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
ES2568509T3 (es) 2009-01-15 2016-04-29 Adaptive Biotechnologies Corporation Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
JP5804521B2 (ja) 2009-05-29 2015-11-04 モルフォシス・アー・ゲー コレクション及びその使用方法
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
RU2014144463A (ru) 2009-06-25 2015-06-20 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения адаптивного иммунитета
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SI3095871T1 (sl) 2010-02-08 2019-06-28 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2011146514A2 (en) * 2010-05-17 2011-11-24 The Board Of Regents Of The University Of Texas System Rapid isolation of monoclonal antibodies from animals
CA2816558C (en) 2010-11-19 2020-12-29 Morphosys Ag A collection and methods for its use
HUE037095T2 (hu) 2011-03-09 2018-08-28 Cell Signaling Technology Inc Eljárások és reagensek monoklonális ellenanyagok elõállítására
RS61946B1 (sr) 2011-08-05 2021-07-30 Regeneron Pharma Humanizovani miševi univerzalnog lakog lakca
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
CA2791109C (en) * 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
US9279159B2 (en) 2011-10-21 2016-03-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
WO2013078455A2 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Proteomic identification of antibodies
ES2683037T3 (es) 2011-12-09 2018-09-24 Adaptive Biotechnologies Corporation Diagnóstico de tumores malignos linfoides y detección de enfermedad residual mínima
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
DK2823060T3 (en) 2012-03-05 2018-05-28 Adaptive Biotechnologies Corp Determination of associated immune receptor chains from frequency-matched subunits
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
US9150905B2 (en) 2012-05-08 2015-10-06 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
US9708654B2 (en) 2012-06-15 2017-07-18 Board Of Regents, The University Of Texas System High throughput sequencing of multiple transcripts
CN105189779B (zh) 2012-10-01 2018-05-11 适应生物技术公司 通过适应性免疫受体多样性和克隆性表征进行的免疫能力评估
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
AU2015227054A1 (en) 2014-03-05 2016-09-22 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10881085B2 (en) 2014-03-21 2021-01-05 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
AU2015339191A1 (en) 2014-10-29 2017-05-18 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
WO2016086029A1 (en) 2014-11-25 2016-06-02 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
AU2016222788B2 (en) 2015-02-24 2022-03-31 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
EP3271403A1 (de) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Nichtmenschliche tiere zur selektion von leichtkettigen variablen regionen zur antigenbindung
US10513733B2 (en) 2015-03-23 2019-12-24 Board Of Regents, The University Of Texas System High throughout sequencing of paired VH and VL transcripts from B cells secreting antigen-specific antibodies
EP3277294B1 (de) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Verfahren zur identifizierung von menschlichen kompatiblen t-zell-rezeptoren spezifisch für ein antigen-ziel
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
WO2019084538A1 (en) 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007713A1 (en) * 1988-12-29 1990-07-12 Cytogen Corporation Molecular recognition units
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
DE60124313T2 (de) * 2001-01-15 2007-05-31 Keryos S.P.A. Dns-vakzine von hypervariablen vh-cdr3 idiotypischen determinanten
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies

Also Published As

Publication number Publication date
EP1415002A2 (de) 2004-05-06
ES2236605T3 (es) 2005-07-16
PT1415002E (pt) 2005-05-31
DE60202877T2 (de) 2006-04-13
EP1415002B1 (de) 2005-02-02
WO2003052416A2 (en) 2003-06-26
CA2471570A1 (en) 2003-06-26
AU2002352394A1 (en) 2003-06-30
DE60202877D1 (de) 2005-03-10
WO2003052416A3 (en) 2003-10-16
GB0130267D0 (en) 2002-02-06
US20060233812A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
ATE288502T1 (de) Gezieltes antikörper-verfahren
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
HUP0400313A2 (hu) Új, biotechnológiai úton előállított, humán terápiára alkalmas szuperantigének
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
ATE406912T1 (de) Immunisierung gegen chlamydia tracheomatis
CY1105389T1 (el) Hpv-e7 ως αγωγη εναντι του ιου θηλωματων ανθρωπου
IS6895A (is) Aðferð til að bera kennsl á, einangra og vinna mótefnavaka við ákveðnum sjúkdómsvaldi
WO2003039462A3 (en) B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
ATE521361T1 (de) Verfahren zur behandlung von gebärmutterhalskrebs
ID30223A (id) Penggunaan antibodi untuk vaksinasi melawan kanker
HUP0301634A2 (hu) Hőmérséklet-érzékeny, élő vakcina Mycoplasma hyopneumoniaera
DE60218473D1 (de) Verfahren zur herstellung polyvalenter bakteriophagenpräparationen zur behandlung bakterieller infektionen
ATE381942T1 (de) Mittel zur behandlung von infektionen mit leishmanien
WO2002072013A8 (en) Method of treating malignancies through induction of blood immune responses
EP1667634A4 (de) Anthrax-vakzine
DK1146889T3 (da) Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407
DE60233936D1 (de) Therapeutische Zusammenseztungen zur Toleranzinduktion
EA200100701A1 (ru) Белки наружной поверхности, их гены и их применение
BR0318688A (pt) polipeptìdeo para o diagnóstico e terapia de leishmania
ATE297745T1 (de) Chemische modifizierung von harn von säugern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1415002

Country of ref document: EP